EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access

Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer

Devalingam Mahalingam, Salih Hanni, Anthony V Serritella, Christos Fountzilas, Joel Michalek, Brian Hernandez, John Sarantopoulos, Paromitta Datta, Ofelia Romero, Sureshkumar Mulampurath Achutan Pillai, John Kuhn, Michael Pollak und 1 weitere

Oncotarget · 2023

DOI: 10.18632/oncotarget.28458 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Oncotarget, 2023. Verfasst von Devalingam Mahalingam und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, University of Texas Health Science Center, San Antonio, TX 77030, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Metformin, Metabolic Syndrome, Insulins. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMetforminMetabolic SyndromeInsulinsMaleHumansAgedAndrogen AntagonistsAndrogensProstate-Specific Antigen

Stichwörter der Autor:innen

androgen deprivation therapyclinical trialmetastaticmetforminprostate cancer

Substanzen

Androgen AntagonistsMetforminAndrogensProstate-Specific AntigenInsulins

Autor:innen und Institutionen

  • Division of Hematology and Oncology, University of Texas Health Science Center, San Antonio, TX 77030, USA.
  • Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA.
  • Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
  • Institute for Drug Development, Mays Cancer Center at University of Texas Health, San Antonio, TX 78229, USA.
  • Audie Murphy VA Hospital, San Antonio, TX 78229, USA.
  • Division of Experimental Medicine, Lady Davis Institute of Medical Research, Jewish General Hospital, McGill University, Montreal, Canada.

Förderung

  • NCI NIH HHS

Zitieren

APA

Mahalingam, D., Hanni, S., Serritella, A. V., Fountzilas, C., Michalek, J., Hernandez, B., Sarantopoulos, J., Datta, P., Romero, O., Pillai, S. M. A., Kuhn, J., Pollak, M., & Thompson, I. M. (2023). Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer. Oncotarget. https://doi.org/10.18632/oncotarget.28458

Vancouver

Mahalingam D, Hanni S, Serritella AV, Fountzilas C, Michalek J, Hernandez B, et al. Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer. Oncotarget. 2023. doi:10.18632/oncotarget.28458

BibTeX
@article{Mahalingam2023,
  author = {Mahalingam, Devalingam and Hanni, Salih and Serritella, Anthony V and Fountzilas, Christos and Michalek, Joel and Hernandez, Brian and Sarantopoulos, John and Datta, Paromitta and Romero, Ofelia and Pillai, Sureshkumar Mulampurath Achutan and Kuhn, John and Pollak, Michael and Thompson, Ian M},
  title = {Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer},
  journal = {Oncotarget},
  year = {2023},
  doi = {10.18632/oncotarget.28458}
}
Kostenlos starten →